IT201700085714A1 - Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. - Google Patents

Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.

Info

Publication number
IT201700085714A1
IT201700085714A1 IT102017000085714A IT201700085714A IT201700085714A1 IT 201700085714 A1 IT201700085714 A1 IT 201700085714A1 IT 102017000085714 A IT102017000085714 A IT 102017000085714A IT 201700085714 A IT201700085714 A IT 201700085714A IT 201700085714 A1 IT201700085714 A1 IT 201700085714A1
Authority
IT
Italy
Prior art keywords
prevention
treatment
therapeutic approach
gluten sensitivity
sensitivity conditions
Prior art date
Application number
IT102017000085714A
Other languages
English (en)
Inventor
Luigi Maiuri
Original Assignee
Luigi Maiuri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luigi Maiuri filed Critical Luigi Maiuri
Priority to IT102017000085714A priority Critical patent/IT201700085714A1/it
Priority to PCT/EP2018/070103 priority patent/WO2019020663A1/en
Priority to EP18749318.4A priority patent/EP3658136A1/en
Priority to US16/633,582 priority patent/US20200206198A1/en
Publication of IT201700085714A1 publication Critical patent/IT201700085714A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
IT102017000085714A 2017-07-26 2017-07-26 Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. IT201700085714A1 (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT102017000085714A IT201700085714A1 (it) 2017-07-26 2017-07-26 Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
PCT/EP2018/070103 WO2019020663A1 (en) 2017-07-26 2018-07-25 CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND / OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS
EP18749318.4A EP3658136A1 (en) 2017-07-26 2018-07-25 Cftr channel activator for use in the treatment and/or prevention of gluten sensitivity conditions
US16/633,582 US20200206198A1 (en) 2017-07-26 2018-07-25 Cftr channel activator for use in the treatment and/or prevention of gluten sensitivity conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000085714A IT201700085714A1 (it) 2017-07-26 2017-07-26 Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.

Publications (1)

Publication Number Publication Date
IT201700085714A1 true IT201700085714A1 (it) 2019-01-26

Family

ID=60294342

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000085714A IT201700085714A1 (it) 2017-07-26 2017-07-26 Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.

Country Status (4)

Country Link
US (1) US20200206198A1 (it)
EP (1) EP3658136A1 (it)
IT (1) IT201700085714A1 (it)
WO (1) WO2019020663A1 (it)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089766A1 (en) * 2004-03-05 2005-09-29 Altana Pharma Ag Novel use for pde5 inhibitors
WO2012023142A2 (en) * 2010-08-18 2012-02-23 Clearfarma Industries Ltd. Functional food compositions and methods
WO2015173551A1 (en) * 2014-05-12 2015-11-19 Verona Pharma Plc New treatment
WO2016210405A2 (en) * 2015-06-26 2016-12-29 University Of Florida Research Foundation, Incorporated Method of treating inflammation using natural compounds and/or diet
WO2017060388A1 (en) * 2015-10-06 2017-04-13 Algipharma As Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3394083B9 (en) * 2015-12-24 2022-04-27 The Regents of the University of California N-[5-[(3,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-methoxy-benzeneacetamide derivatives and related compounds as cftr activators for treating constipation or cholestasis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089766A1 (en) * 2004-03-05 2005-09-29 Altana Pharma Ag Novel use for pde5 inhibitors
WO2012023142A2 (en) * 2010-08-18 2012-02-23 Clearfarma Industries Ltd. Functional food compositions and methods
WO2015173551A1 (en) * 2014-05-12 2015-11-19 Verona Pharma Plc New treatment
WO2016210405A2 (en) * 2015-06-26 2016-12-29 University Of Florida Research Foundation, Incorporated Method of treating inflammation using natural compounds and/or diet
WO2017060388A1 (en) * 2015-10-06 2017-04-13 Algipharma As Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2017 (2017-04-01), VAN BUITEN CHARLENE B ET AL: "Inhibition of Gliadin Digestion by Green Tea Polyphenols and the Potential Implications for Celiac Disease", XP002779311, Database accession no. PREV201700758019 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1 June 2017 (2017-06-01), GILMARTIN G ET AL: "Phase 1 initial results evaluating novel CFTR amplifier PTI-428 in CF subjects", XP002779310, Database accession no. EMB-620749495 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1 June 2017 (2017-06-01), POPLAWSKA K ET AL: "3-months follow up in patients with cystic fibrosis homozygous for F508Del-CFTR undergoing lumacaftor and ivacaftor (LUM/IVA) therapy showed improvements in intestinal inflammation marker", XP002779309, Database accession no. EMB-620749305 *
DE STEFANO ET AL: "Lycopene, quercetin and tyrosol prevent macrophage activation induced by gliadin and IFN-gamma", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 566, no. 1-3, 24 May 2007 (2007-05-24), pages 192 - 199, XP022095358, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2007.03.051 *
FASEB JOURNAL, vol. 31, no. Suppl. 1, April 2017 (2017-04-01), EXPERIMENTAL BIOLOGY MEETING; CHICAGO, IL, USA; APRIL 22 -26, 2017, pages 974.23, ISSN: 0892-6638(print) *
GILMARTIN G ET AL: "Phase 1 initial results evaluating novel CFTR amplifier PTI-428 in CF subjects", JOURNAL OF CYSTIC FIBROSIS 20170601 ELSEVIER B.V. NLD, vol. 16, no. Supplement 1, 1 June 2017 (2017-06-01), pages S23 CONF 20170607 to 20170610 Seville - 40th Euro, ISSN: 1873-5010 *
MARK SAFE ET AL: "Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor", ANNALS OF THE AMERICAN THORACIC SOCIETY, 1 February 2016 (2016-02-01), pages 1 - 2, XP055460829, Retrieved from the Internet <URL:https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.201510-669LE> [retrieved on 20180319] *
ONUR CIL ET AL: "CFTR Activator Increases Intestinal Fluid Secretion and Normalizes Stool Output in a Mouse Model of Constipation", CMGH CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, vol. 2, no. 3, 1 May 2016 (2016-05-01), pages 317 - 327, XP055460376, ISSN: 2352-345X, DOI: 10.1016/j.jcmgh.2015.12.010 *
POPLAWSKA K ET AL: "3-months follow up in patients with cystic fibrosis homozygous for F508Del-CFTR undergoing lumacaftor and ivacaftor (LUM/IVA) therapy showed improvements in intestinal inflammation marker", JOURNAL OF CYSTIC FIBROSIS 20170601 ELSEVIER B.V. NLD, vol. 16, no. Supplement 1, 1 June 2017 (2017-06-01), pages S77 20170607 to 20170610 Seville - S78 CONF, ISSN: 1873-5010 *
S. RASHTAK ET AL: "Review article: coeliac disease, new approaches to therapy", ALIMENTARY PHARMACOLOGY & THERAPEUTICS., vol. 35, no. 7, 13 February 2012 (2012-02-13), GB, pages 768 - 781, XP055460510, ISSN: 0269-2813, DOI: 10.1111/j.1365-2036.2012.05013.x *

Also Published As

Publication number Publication date
US20200206198A1 (en) 2020-07-02
EP3658136A1 (en) 2020-06-03
WO2019020663A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
DK3731772T3 (da) Systems for the treatment of disease states and disorders
DK3600281T3 (da) Kombinationsbehandling til behandling eller forebyggelse af tumorer
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
DK3740504T3 (da) CD70 kombinationsterapi
FI20145492A (fi) Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen
DK3478679T3 (da) 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
EP3497452A4 (en) DIAGNOSIS, PREVENTION AND / OR TREATMENT OF AUTOIMMUNE DISEASES
EP3615056A4 (en) METHODS AND COMPOSITIONS FOR THE SCREENING AND TREATMENT OF CANCER
IL266047A (en) Methods and preparations for the treatment of Fabry disease
DK3532064T3 (da) Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
HK1257236A1 (zh) 預防和治療高脂血症的藥物及其用途
EP3428178A4 (en) PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF
IT201700060506A1 (it) Composizione per la prevenzione e/o il trattamento di patologie associate a infiammazione e/o iperalgesia
IT201700121764A1 (it) Composizione per il trattamento e/o la prevenzione di patologie neurodegenerative.
ITUA20161865A1 (it) Uso di lentinano per il trattamento e la prevenzione di endometriosi.
BR112017005993A2 (pt) derivados de peptídeo inovadores e usos dos mesmos
BR112018005305A2 (pt) agente profilático ou terapêutico da queratite fungal
EP3428179A4 (en) PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF
ITUB20160121A1 (it) Gabapentina oftalmica per il trattamento di ulcere corneali
IT201700085714A1 (it) Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
GB201519258D0 (en) Newly identified wnt/beta-catenin signal transduction inhibitors and the use thereof in the treatment or prevention of diseases and conditions.
MA55467A (fr) Utilisations thérapeutiques de dulaglutide
IT201700048750A1 (it) Composizione per il trattamento di afte e ulcere buccali